CRISPR Therapeutics' CTX310 Gene Therapy Shows Sustained Cholesterol Reduction in Phase 1a Trial

CRISPR Therapeutics announced Phase 1a clinical trial results for CTX310, an investigational gene-editing therapy. A single dose demonstrated deep and durable reductions in ANGPTL3, triglycerides, and LDL cholesterol, sustained for one year. These findings, presented at the ESC Congress 2026 and published in The New England Journal of Medicine, suggest potential for a new treatment approach for high cholesterol.